International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR
Authors:
Top Cited Papers
Open Access
- 10 March 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (8) , 709-719
Abstract
PURPOSE: There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS: Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual consensus meeting (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS: Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION: This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation—ultimately contributing to the development of safer, more effective therapies.Keywords
This publication has 66 references indexed in Scilit:
- Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug developmentCPT: Pharmacometrics & Systems Pharmacology, 2024
- Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical ResearchJAMA, 2022
- Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.govCancer Medicine, 2021
- Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical TrialsJAMA Oncology, 2020
- Incorporating patient‐reported outcomes in dose‐finding clinical trialsStatistics in Medicine, 2019
- PROMIS®-29 v2.0 profile physical and mental health summary scoresQuality of Life Research, 2018
- Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial ProtocolsJAMA, 2018
- Reporting of Patient-Reported Outcomes in Randomized TrialsJAMA, 2013
- Reliability of adverse symptom event reporting by cliniciansQuality of Life Research, 2011
- Patient-reported outcomes measurement information system (PROMIS) domain names and definitions revisions: further evaluation of content validity in IRT-derived item banksQuality of Life Research, 2010